Company news
Imagenebio, Inc. (NASDAQ:IMA) news
Imagenebio, Inc. news releases on 6ix. Latest, Oct 2, 2026: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026
ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
August 18, 2026
ImageneBio Reports Second Quarter 2026 Financial Results
August 5, 2026
ImageneBio Appoints Matt Robbins as General Counsel
July 7, 2026
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
May 7, 2026
ImageneBio Announces $30 Million Private Placement
April 12, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
March 10, 2026
ImageneBio to Participate in Leerink Global Healthcare Conference
February 26, 2026
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
February 9, 2026
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
November 11, 2025
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
November 6, 2025
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
July 25, 2025